Home » Stocks » SLP

Simulations Plus, Inc. (SLP)

Stock Price: $54.66 USD -0.14 (-0.26%)
Updated Jun 22, 2021 4:00 PM EDT - Market closed
Market Cap 1.10B
Revenue (ttm) 45.69M
Net Income (ttm) 10.81M
Shares Out 20.11M
EPS (ttm) 0.54
PE Ratio 101.22
Forward PE 119.05
Dividend $0.24
Dividend Yield 0.44%
Trading Day June 22
Last Price $54.66
Previous Close $54.80
Change ($) -0.14
Change (%) -0.26%
Day's Open 54.64
Day's Range 54.06 - 55.10
Day's Volume 48,407
52-Week Range 49.34 - 90.84

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus CEO Shawn O'Connor will participate in Craig-Hallum's 18th Annual Institutional Investor Conference on June 2, 2021.

3 weeks ago - Business Wire

LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus CEO Shawn O'Connor will participate in the 16th Annual Needham Virtual Technology & Media Conference on Thursday, May 20, 2021.

1 month ago - Business Wire

LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus (SLP) announced today that its securities will be listed on The Nasdaq Global Select Market with the open of business on May 13, 2021

1 month ago - Business Wire

LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus releases ADMET Predictor APX.2, its flagship machine learning platform with new & enhanced capabilities in discovery PBPK simulations

1 month ago - Business Wire

LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus announced today that the US FDA renewed its licensing to the DILIsym Services division's flagship QST software platform, DILIsym.

2 months ago - Business Wire

Simulations Plus' (SLP) fiscal second-quarter results benefit from strong performance of the company's higher-margin software business.

2 months ago - Zacks Investment Research

Simulations Plus (SLP) delivered earnings and revenue surprises of 7.14% and 1.68%, respectively, for the quarter ended February 2021. Do the numbers hold clues to what lies ahead for the stock?

2 months ago - Zacks Investment Research

Shares of Simulations Plus (NASDAQ:SLP) moved higher after the company reported Q2 results. Quarterly Results Earnings per share increased 25.00% over the past year to $0.15, which beat the estimate of ...

2 months ago - Benzinga

LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus today reported record 2nd quarter results for FY2021. Net revenue of $13.1 million, up 27% over 2QFY20; YTD revenue of $23.8 million.

2 months ago - Business Wire

On Monday, April 12, Simulations Plus (NASDAQ:SLP) will release its latest earnings report. Benzinga's report can help you figure out the ins and outs of the earnings release.

2 months ago - Benzinga

Simulations Plus (SLP) fiscal second-quarter results are likely to reflect gains from solid uptick in modeling and simulations workflow platform for drug development across pharma and biotech industries.

2 months ago - Zacks Investment Research

LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus reports excellent results from its Artificial Intelligence-driven Drug Design (AIDD) module in ADMET Predictor in testing by partner.

2 months ago - Business Wire

LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus announced today that it will report its 2nd quarter fiscal year 2021 results on Monday, April 12, 2021, with a webcast at 4:15 pm ET.

2 months ago - Business Wire

LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus announced the formation of a Scientific Advisory Board to guide the development of its RENAsym QST kidney injury software platform.

3 months ago - Business Wire

LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus announced the successful launch of its 2021 MIDD+ Scientific Conference with speakers from industry, academia, & regulatory agencies.

3 months ago - Business Wire

LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus CEO Shawn O'Connor will present at Oppenheimer's 31st Annual Healthcare Conference on March 16, 2021, beginning at 2:30 p.m. ET.

3 months ago - Business Wire

LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus announced that its DILIsym division and the University of Pittsburgh Drug Discovery Institute jointly received a Phase I SBIR grant.

3 months ago - Business Wire

What's better than rapid growth and a dividend payment?

Other stocks mentioned: ABBV, PINC
4 months ago - The Motley Fool

LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus will host fireside chat at BTIG's Virtual MedTech, Digital Health, Life Science & Diagnostic Tools Conference on Feb. 18, at 12pm ET.

4 months ago - Business Wire

LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus today announced the release of GastroPlus 9.8.1 with key enhancements to improve efficiency and inform regulatory decision making.

4 months ago - Business Wire

LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus today announced an agreement to distribute Lixoft's MonolixSuite in China with Mosim, one of China's leading clinical CROs.

4 months ago - Business Wire

LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus today announced that it is partnering with the Institute of Pharmaceutical Sciences (ICF) in Brazil, to expand into South America.

4 months ago - Business Wire

LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus today announced that it has awarded a grant to Uganda's Makerere University funding upgraded infrastructure to facilitate research.

5 months ago - Business Wire

Simulations Plus (SLP) fiscal first-quarter results reflect solid software and service revenue growth. However, coronavirus crisis affected renewals.

5 months ago - Zacks Investment Research

The company continues to anticipate swift, double-digit revenue growth over the next several quarters.

5 months ago - The Motley Fool

New York, New York--(Newsfile Corp. - January 12, 2021) -  Levi & Korsinsky announces it has commenced an investigation of Simulations Plus, Inc. (NASDAQ: SLP) concerning possible breaches of fiduciary ...

5 months ago - Newsfile Corp

LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus announced that CEO Shawn O'Connor will present at the 23rd Annual Needham Virtual Growth Conference on January 14, 2021, at 2pm ET.

5 months ago - Business Wire

LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus today announced a new funded collaboration with a large pharmaceutical partner to enhance PBPK/PD models for pulmonary therapeutics.

5 months ago - Business Wire

Simulations Plus, Inc. (SLP) CEO Shawn O'Connor on Q1 2021 Results - Earnings Call Transcript

5 months ago - Seeking Alpha

Simulations Plus (SLP) delivered earnings and revenue surprises of 9.09% and 1.35%, respectively, for the quarter ended November 2020. Do the numbers hold clues to what lies ahead for the stock?

5 months ago - Zacks Investment Research

Shares of Simulations Plus (NASDAQ:SLP) were flat after the company reported Q1 results. Quarterly Results Earnings per share increased 9.09% year over year to $0.12, which beat the estimate of $0.11.

5 months ago - Benzinga

LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus today reported record 1st quarter results for FY2021. Net revenues of $10.7 million increased 14%; net income was up 21% over 1QFY20.

5 months ago - Business Wire

Simulations Plus (NASDAQ:SLP) releases its next round of earnings this Monday, January 11. Get the latest predictions in Benzinga's essential guide to the company's Q1 earnings report.

5 months ago - Benzinga

Simulations Plus (SLP) fiscal first-quarter results are likely to reflect gains from solid uptick in modeling and simulations workflow platform for drug development across pharma and biotech industries.

5 months ago - Zacks Investment Research

LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus today announced a new funded collaboration to enhance its GastroPlus ACAT model with novel mechanisms for oral peptide formulations.

5 months ago - Business Wire

LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus announced today that it will report its first quarter fiscal year 2021 results on Monday, Jan. 11, 2021, with a webcast at 4:15 pm ET

5 months ago - Business Wire

We discuss three software stocks -- COUP, NUAN and SLP -- which might not sustain market beating run in 2021, owing to persistent macroeconomic weakness across SMBs induced by coronavirus outbreak.

Other stocks mentioned: COUP, NUAN
6 months ago - Zacks Investment Research

LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus today announced that it has published its inaugural Environmental, Social and Governance (ESG) report on its website's Investors page

6 months ago - Business Wire

LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus today announced the appointment of Will Frederick as CFO, succeeding John Kneisel who is retiring after 7 years with the Company.

6 months ago - Business Wire

Simulations Plus (SLP) fiscal fourth-quarter results reflect solid software and service revenue growth. However, coronavirus crisis affected renewals.

7 months ago - Zacks Investment Research

Simulations Plus' (SLP) CEO Shawn O'Connor on Q4 2020 Results - Earnings Call Transcript

7 months ago - Seeking Alpha

Simulations Plus (SLP) delivered earnings and revenue surprises of 20.00% and 0.85%, respectively, for the quarter ended August 2020. Do the numbers hold clues to what lies ahead for the stock?

7 months ago - Zacks Investment Research

Shares of Simulations Plus (NASDAQ:SLP) fell 2.16% in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share were unchanged 0.00% over the past year to $0.11, w...

7 months ago - Benzinga

LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus today reported results for the 4th quarter and fiscal year 2020. Full FY20 revenues increased 22.4%; 4QFY20 revenues increased 18.9%.

7 months ago - Business Wire

LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus announced today that it will report its 4th quarter and fiscal year 2020 results on Mon., Nov. 16, 2020, with a webcast at 4:15 pm ET

7 months ago - Business Wire

LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus announced today that CEO Shawn O'Connor will be participating in the Credit Suisse Virtual Healthcare Conference on Nov. 10, 2020.

7 months ago - Business Wire

Simulations Plus (SLP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

7 months ago - Zacks Investment Research

ORCL vs. SLP: Which Stock Is the Better Value Option?

Other stocks mentioned: ORCL
8 months ago - Zacks Investment Research

LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus today announced the release of GastroPlus 9.8 with key improvements to non-oral delivery models, virtual bioequivalence, and DDIs.

8 months ago - Business Wire

LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus announced today that its Board of Directors has declared a cash dividend of $0.06 per share to be distributed on Nov. 2, 2020.

8 months ago - Business Wire

About SLP

Simulations Plus, Inc. develops drug discovery and development software for mechanistic modeling and simulation, and prediction of properties of molecules utilizing artificial-intelligence- and machine-learning-based technology worldwide. The company offers GastroPlus, which simulates the absorption, pharmacokinetics (PK), pharmacodynamics, and drug-drug interactions of compounds administered to humans and animals; DDDPlus that simulates in vitro laboratory experiments; and MembranePlus, which simulates laboratory experiments. It also provides ... [Read more...]

Industry
Health Information Services
IPO Date
Jun 18, 1997
Stock Exchange
NASDAQ
Ticker Symbol
SLP
Full Company Profile

Financial Performance

In 2020, SLP's revenue was $41.59 million, an increase of 22.43% compared to the previous year's $33.97 million. Earnings were $9.33 million, an increase of 8.72%.

Financial Statements

Analyst Forecasts

According to 4 analysts, the average rating for SLP stock is "Buy." The 12-month stock price forecast is 84.67, which is an increase of 54.90% from the latest price.

Price Target
$84.67
(54.90% upside)
Analyst Consensus: Buy